French biotech outfit Core Biogenesis has unveiled head-to-head clinical results of its breakthrough actives Peauvita and Peauforia versus retinol at NYSCC Suppliers’ Day in New York booth 579.
Backed by clinical results in just 14 days, Peauvita and Peauforia visibly improve skin firmness, reduce fine lines, diminish hyperpigmentation, and restore the skin barrier.
The company says this offers indie brands and multinationals alike a powerful edge in a results-driven market.
At the heart of this performance is Core Biogenesis’ patented oleosome-growth factor fusion technology, a proprietary plant biotechnology platform that stabilizes and delivers delicate growth factors deep into the skin — something traditional methods have struggled to achieve.
New data will be revealed to showcase how this powerful technology compares favourably to gold standard retinol in vivo.
Unlike conventional actives that degrade quickly or sit on the surface of the skin, Core’s bioengineered growth factors are 10x more stable and deliver deeper into both the epidermis and dermis. The result? Highly potent skincare actives that are clean, effective, and formulation-ready.
“Our mission is to make biotechnology accessible to every skin care brand, especially the rising indie innovators shapingthe future of beauty,” said Tony Abboud, chief commercial officer and Core Biogenesis.
“We’re excited to connect with founders at NYSCC and show what’s truly possible in just two weeks."
